Precise prediction model and simplified scoring system for sustained combined response to interferon-α

World Journal of Gastroenterology

Volumn 16, Issue 27, 2010, Pages 3465-3471

  Mao, Qian Guo ^a   Pan, Jin Shui ^b   Fang, Kuang Nan ^c   Zhang, Ru Mian ^a   Hong, Qing Yang ^c   Song, Min Ning ^d   Zhu, Jian Ping ^c   Huang, Wen Qi ^d   Chen, Li Min ^e   Hong, Mei Zhu ^d  

^a Xiamen Hospital of Traditional Chinese Medicine   (China)

^b ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c XIAMEN UNIVERSITY   (China)

^d The Affiliated Chenggong Hospital of Xiamen University   (China)

^e Division of Infectious Diseases   (China)

Author keywords

Chronic hepatitis b; Interferon ; Patient selection; Predictive model; Scoring system; Treatment outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ACCURACY; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; SCHOOL CHILD; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CONTROLLED STUDY; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; THEORETICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALGORITHMS; CHILD; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MODELS, THEORETICAL; ROC CURVE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954838425     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i27.3465     Document Type: Article

References (19)

1. Hepatitis B. Fact sheet WHO/204. Geneva: World Health Organization, October 2000. Accessed on Nov 25, 2009. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html
2. Liu J, Fan D. Hepatitis B in China. Lancet 2007; 369: 1582-1583
3. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539
4. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, Clementi M, Colombo M. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 1621-1625
5. Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14: 221-225
6. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283
7. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242
8. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl) 2007; 120: 2159-2173
9. Luo K, Mao Q, Karayiannis P, Liu D, Liu Z, Zhou Y, Feng X, Zhu Y, Guo Y, Jiang R, Zhou F, Peng J, Hou J. Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study. J Viral Hepat 2008; 15: 684-689
10. Gish RG, Lau DT, Schmid P, Perrillo R. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B. Am J Gastroenterol 2007; 102: 2718-2723
11. Lampertico P, Del Ninno E, Viganò M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756-763
12. Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, Wei L, Wang GQ, Tanaka Y, Mizokami M, Si CW. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007; 44: 541-548
13. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-651
14. Hastie T, Tibshirani R, Friedman J. The elements of statistical learning. 1st ed. New York: Springer, 2001: 214-217
15. Zeng G, Wang Z, Wen S, Jiang J, Wang L, Cheng J, Tan D, Xiao F, Ma S, Li W, Luo K, Naoumov NV, Hou J. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat 2005; 12: 609-617
16. Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B. Hepatol Int 2008; 2: 140-146
17. Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303
18. Chen YP, Dai L, Wang JL, Zhu YF, Feng XR, Hou JL. Model consisting of ultrasonographic and simple blood indexes accurately identify compensated hepatitis B cirrhosis. J Gastroenterol Hepatol 2008; 23: 1228-1234
19. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alphainterferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763